|
1.
|
|
10 p, 1.2 MB |
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
/
Argilés Martínez, Guillem ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Valladares-Ayerbes, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viéitez, J.M. (Hospital Universitario Central de Asturias) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Tobeña, M. (Institut d'Investigació Biomèdica Sant Pau) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rodríguez-Garrote, M. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Rivera, F. (Instituto de Investigación Marqués de Valdecilla) ;
Goldberg, R.M. (West Virgina University Cancer Institute) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Bennouna, J. (CHU-Nante) ;
Ciardiello, Fortunato ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Falcone, A. (Gustave Roussy) ;
Goldberg, R. ;
Argilés, None (Memorial Sloan Kettering Cancer Center) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Limón, M.L. (H. Virgen del Rocío) ;
Valladares, M. (H. Virgen del Rocío) ;
Jiménez, P. (H. Universitario Central de Asturias) ;
Vieitez, J.M. (H. Universitario Central de Asturias) ;
Grávalos, C. (H. 12 de Octubre) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Sastre Valera, Javier (H. Universitario Clínico San Carlos) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Aranda Aguilar, Enrique (H. Universitario Reina Sofía) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rguez Garrote, M. (H. Ramón y Cajal) ;
Guillén, C. (H. Ramón y Cajal) ;
Rivera, M.F. (H. Marqués de Valdecilla) ;
Safont, J. (H. General Universitario) ;
Hiret, S. (Institut de Cancérologie de l'Ouest) ;
Bennouna, J. (CHU-Nante) ;
Pannier, D. (Centre Oscar Lambret) ;
Malka, D. (Gustave Roussy) ;
Falcone, A. (Gustave Roussy) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Universitat Autònoma de Barcelona
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). [...]
2022 -  10.1016/j.ejca.2022.09.037
European journal of cancer, Vol. 177 (december 2022) , p. 154-163
|
|
|
2.
|
|
5 p, 332.1 KB |
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
/
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Giuliani, Rosa (San Camillo Forlanini Hospital) ;
Arnold, Dirk (CUF Hospitals) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Casali, Paolo Giovanni (Fondazione IRCCS National Cancer Institute) ;
Cervantes, Andrés (Clinic Hospital) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Jassem, Jacek (Medical University of Gdansk) ;
Pentheroudakis, George (University of Ioannina) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Rauh, Stefan (Hospital Center Emile Mayrisch) ;
Zielinski, Christoph C. (Medical University of Vienna) ;
Stahel, Rolf A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Voest, Emile (University Hospital Zurich (Suïssa)) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Ciardiello, Fortunato (Second University of Naples) ;
Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 - 10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)
|
|
|
3.
|
|
5 p, 637.4 KB |
Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
/
Lordick, Florian (Leipzig University Medical Center) ;
Obermannova, Radka (Masaryk University) ;
Vola, Doris (European Society for Medical Oncology) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Mcgregor, Keith (European Society for Medical Oncology) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Ciardiello, Fortunato (Second University of Naples) ;
Cervantes, Andrés (Universitat de València)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)
|
|
|
4.
|
|
19 p, 418.6 KB |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Grothey, Axel (West Cancer Center, Germantown, TN) ;
Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ;
Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Wasan, Harpreet (Hammersmith Hospital (Londres)) ;
Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ;
Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ;
Gollerkeri, Ashwin (Array BioPharma Inc) ;
Christy-Bittel, Janna (Array BioPharma Inc) ;
Maharry, Kati (Array BioPharma Inc) ;
Sandor, Victor (Array BioPharma Inc) ;
Schellens, Jan H. M. (Utrecht University) ;
Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut de Recerca (VHIR)
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469
|
|
|
5.
|
|
9 p, 325.6 KB |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ;
Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ;
Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ;
Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ;
Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ;
Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ;
Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ;
Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ;
Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Taniguchi, H. (Aichi Cancer Center Hospital) ;
Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ;
Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ;
Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ;
Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ;
Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ;
Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963
|
|
|
6.
|
|
10 p, 1016.0 KB |
Global cancer control : responding to the growing burden, rising costs and inequalities in access
/
Prager, Gerald W. (Medical University of Vienna) ;
Braga, Sofia (Instituto CUF Oncologia) ;
Bystricky, Branislav (Faculty Hospital Trencin) ;
Qvortrup, Camilla (Odense University Hospital (Dinamarca)) ;
Criscitiello, Carmen (Istituto Europeo di Oncologia) ;
Esin, Ece (Ankara Oncology Education and Research Hospital) ;
Sonke, Gabe S. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ;
Karamouzis, Michalis (National and Kapodistrian University of Athens) ;
Strijbos, Michiel (AZ KLINA Hospitals) ;
Yazici, Ozan (Ankara Numune Education and Research Hospital) ;
Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ;
Banerjee, Susana (Royal Marsden Hospital (Regne Unit)) ;
Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Zielinski, Christoph C. (Medical University Vienna, General Hospital, and Vienna Cancer Center) ;
Casali, Paolo Giovanni (Istituto Nazionale Tumori) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Jezdic, Svetlana (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Bricalli, Gracemarie (European Society for Medical Oncology) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO open, Vol. 3 (february 2018)
|
|
|
7.
|
|
8 p, 207.5 KB |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer
/
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Roselló, Susana (Universitat de València. Biomedical Research Institute) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Laffranchi, B. (Merck Serono SA) ;
Jego, V (Merck Serono SA) ;
von Richter, O. (Merck KGaA) ;
Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
